Arch Therapeutics Announces Distribution Agreement with Buffalo Supply, Inc.
Partnership provides US government facilities access and product distribution supportFRAMINGHAM, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc....
Day: January 4, 2021
Aquestive Therapeutics to Present at Two Upcoming Investor Conferences
WARREN, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and...
Nephros Provides Year-End Technology Update, Including HDF Program Status
HDF Assist Device Complete; Special 510(k) to be Filed in Early 2021 Nephros Granted Patent Covering Technology in HDF Assist...
Leading Independent Proxy Advisory Firm ISS Recommends BridgeBio Pharma and Eidos Therapeutics Stockholders Vote “FOR” Proposed Merger
PALO ALTO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced that leading proxy advisory...
Kaleido Biosciences Announces Completion of Enrollment of 350 Subjects in Controlled Study of KB109 in the Treatment of Mild-to-Moderate COVID-19
Topline data for two studies of KB109 are expected in the first quarter of 2021LEXINGTON, Mass., Jan. 04, 2021 (GLOBE...
Helius Medical Technologies, Inc. to Present at Four Upcoming Investor Conferences in January
NEWTOWN, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech...
Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences
DEVON, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid...
Harpoon Therapeutics Doses First Patient with HPN328, an Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer and other DLL3-Associated Tumors
HPN328, Harpoon’s fourth TriTAC® T cell engager, enters clinical developmentSOUTH SAN FRANCISCO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Harpoon...
Ascendis Pharma A/S Announces Participation in 39th Annual J.P. Morgan Healthcare Conference
COPENHAGEN, Denmark, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative...
Myriad Genetics CEO Paul J. Diaz to Present at 39th Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc. (NASDAQ:...
Precision BioSciences to Present at the Annual J.P. Morgan Healthcare Conference
DURHAM, N.C., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to...
Passage Bio Receives FDA Clearance of IND Application for Lead Gene Therapy Candidate PBGM01 for Treatment of Infantile GM1 Gangliosidosis
FDA clearance marks second regulatory authorization for global Phase 1/2 clinical trial, Imagine-1 study, expected to dose first patient in first...
SI-BONE, Inc. Announces that Updated ISASS Policy and Guidelines on MIS SI Joint Fusion Support Only Lateral Transiliac MIS Procedures
SANTA CLARA, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated...
G1 Therapeutics Announces Appointment of William C. Roberts as Vice President, Investor Relations & Corporate Communications
- Company also reports inducement grant under Nasdaq Listing Rule 5635(c)(4) - RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2021 (GLOBE...
Autolus Therapeutics to participate in Investor Conferences through January
LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell...
Freeline to participate at Conferences during January 2021
LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully...
Matinas BioPharma Announces FDA Conditional Acceptance of LYPDISO™ as the Brand Name for MAT9001
BEDMINSTER, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused...
Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference
CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing innovative medicines...
AzurRx BioPharma Announces $8.0 Million Offerings
DELRAY BEACH, Fla., Jan. 04, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a company...
BiocurePharm, Korea (BPK) Signs MOU With Symbasis GmbH to Develop CAR-T Therapy for Chronic Lymphocyte Leukemia (CLL)
Vancouver, British Columbia--(Newsfile Corp. - January 4, 2021) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) (CURE or the Company)...